IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Immix Biopharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$8.22+0.24 (+3.01%)

Close on Oct 19, 2026

Market cap: $524.20M
P/E (TTM): –
Dividend yield: –

Immix Biopharma, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	94	18	18	13	18	0.39	–
Short-Term Investments	6.48	–	–	–	–	–	–
Cash & Short-Term Investments	100	18	18	13	18	0.39	–
Prepaid Expenses & Other	0.83	0.54	1.11	1.21	0.52	0.01	–
Other Current Assets	0.15	0.03	0.04	0.08	–	–	–
Total Current Assets	101	20	20	15	18	0.53	–
Property, Plant & Equipment	2.52	1.74	0.05	0.00	0.01	0.01	–
Gross Property, Plant & Equipment	2.81	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	0.97	0.99	–	–	–	–	–
Other Long-Term Assets	0.02	0.02	–	0.01	–	–	–
Total Assets	105	23	20	15	18	0.54	–
Accounts Payable	5.44	5.39	1.43	0.14	0.14	0.25	–
Current Portion of Leases	0.14	0.07	–	–	–	–	–
Total Current Liabilities	10	8.69	3.72	1.27	0.20	5.27	–
Long-Term Leases	0.93	1.01	–	–	–	–	–
Operating Lease Liabilities	1.07	1.07	–	–	–	–	–
Total Liabilities	11	9.70	3.72	1.75	0.20	5.27	–
Common Stock	0.01	0.00	0.00	0.00	0.00	0.00	–
Additional Paid-In Capital	198	88	70	51	48	0.51	–
Retained Earnings	-104	-75	-53	-38	-30	-5.37	–
Treasury Stock	-0.10	-0.10	-0.10	-0.10	–	–	–
Comprehensive Income & Other	0.06	0.00	0.13	0.09	0.13	0.13	–
Shareholders' Equity	94	13	16	13	18	-4.73	-3.65
Noncontrolling Interest	–	–	-0.20	–	–	–	–
Total Equity	94	13	16	13	18	-4.73	-3.65
Total Liabilities & Equity	105	23	20	15	18	0.54	–
Shares Outstanding(shares)	53	28	20	14	13	3.38	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -54.9%

Financial strength

Current ratio: 25.13
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2424.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 2.29
Dividend yield: –